---
title: "Sun Pharmaceutical Industries Ltd (SUNPHARMA) — Share Price, Financials & Analysis"
symbol: "SUNPHARMA"
company: "Sun Pharmaceutical Industries Ltd"
canonical: "https://tapetide.com/stocks/SUNPHARMA"
isin: "INE044A01036"
nse_symbol: "SUNPHARMA"
bse_code: "524715"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
market_cap_cr: 442293.41
generated_at: "2026-09-13T20:00:00.796Z"
---

# Sun Pharmaceutical Industries Ltd (SUNPHARMA)

Canonical page: https://tapetide.com/stocks/SUNPHARMA

## Company

- **NSE Symbol:** SUNPHARMA
- **BSE Code:** 524715
- **ISIN:** INE044A01036
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 1995-02-08
- **CEO:** Mr. Dilip Shantilal Shanghvi
- **Employees:** 43000
- **Face Value:** ₹1
- **F&O Eligible:** Yes
- **Website:** sunpharma.com

## About

Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market.[1] It is the largest pharmaceutical company in India.[2]

## Latest Price

- **Price:** ₹1840
- **Change:** -21 (-1.13%)
- **Open:** ₹1845
- **Day High:** ₹1854.5
- **Day Low:** ₹1834
- **Previous Close:** ₹1861
- **Volume:** 1445071
- **As Of:** 2026-09-11T10:20:24+00:00

## Key Fundamentals

Observed at 2026-09-11T04:43:51.565092Z.

- **Market Cap:** ₹442293.41 Cr
- **Classification:** Largecap
- **P/E (reported):** 36.9
- **P/E (TTM):** 36.5
- **EPS (TTM):** ₹50.41
- **EPS (reported):** ₹43.95
- **Book Value:** ₹348.31
- **Price to Book:** 5.35
- **Dividend Yield:** 0.86%
- **ROE:** 13.79%
- **ROCE:** 17.94%
- **Debt to Equity:** 0.06
- **Revenue (yearly):** ₹61673.9 Cr
- **Net Income:** ₹11564.5 Cr
- **EBITDA:** ₹19703.1 Cr
- **52-Week High:** ₹2046.9
- **52-Week Low:** ₹1548
- **RSI (14):** 37.54

## Tapetide Score

- **Score:** 53 / 100
- **Score date:** 2026-09-04
- **Archetype:** No Dominant Pattern
- **What it means:** The three pillars do not combine into a recognisable pattern. Read them individually rather than looking for one story — the lack of a pattern is itself the finding.
- **Pillar profile:** Quality: Average · Valuation: Cheap · Momentum: Falling
- **Percentile:** 61 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 81.63 | 9% |
| growth | 26.66 | 9% |
| momentum | 24.02 | 12% |
| ownership | 45.55 | 24% |
| quality | 56.77 | 22% |
| valuation | 70.89 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 34.1%

### Weaknesses

- The company has delivered a poor sales growth of 11.8% over past five years.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -11.75% | 2.34% | 38.23% |
| ebitda margin growth | 10.55% | 1.46% | 10.86% | 12.14% |
| net income growth | 7.07% | 5.32% | 13% | 17% |
| revenue growth | 5.92% | 12.69% | 10% | 12% |
| roce | 15.43% | -5.18% | 8.53% | 15.58% |
| roe | 7.07% | -8.98% | 14.44% | 106.75% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 12192 | 12381 | 11983 | 12653 | 13291 | 13675 | 12959 | 13851 | 14478 | 15521 | 14612 | 15300 |
| Expenses | 9013 | 8904 | 8948 | 9045 | 9352 | 9666 | 9243 | 9550 | 9951 | 10572 | 10658 | 10882 |
| Operating Profit | 3179 | 3477 | 3035 | 3608 | 3939 | 4009 | 3716 | 4302 | 4527 | 4948 | 3954 | 4418 |
| OPM % | 26 | 28 | 25 | 29 | 30 | 29 | 29 | 31 | 31 | 32 | 27 | 29 |
| Other Income | 294 | 180 | 504 | 533 | 354 | 149 | 251 | -354 | 470 | 89 | 458 | 520 |
| Interest | 49 | 35 | 74 | 62 | 69 | 52 | 49 | 75 | 100 | 78 | 86 | 100 |
| Depreciation | 633 | 622 | 650 | 655 | 626 | 631 | 664 | 701 | 730 | 732 | 775 | 739 |
| Profit before tax | 2791 | 3000 | 2816 | 3424 | 3598 | 3476 | 3254 | 3173 | 4168 | 4227 | 3551 | 4099 |
| Tax % | 14 | 14 | 5 | 16 | 16 | 16 | 34 | 27 | 25 | 20 | 23 | 29 |
| Net Profit | 2385 | 2561 | 2659 | 2861 | 3037 | 2913 | 2154 | 2293 | 3125 | 3381 | 2710 | 2901 |
| EPS in Rs | 9.9 | 10.52 | 11.06 | 11.82 | 12.67 | 12.1 | 8.96 | 9.5 | 13 | 14.04 | 11.31 | 12.06 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 26489 | 29066 | 32838 | 33498 | 38654 | 43886 | 48497 | 52578 | 58462 | 59911 |
| Expenses | 20858 | 22689 | 25855 | 25028 | 28397 | 32235 | 35479 | 37464 | 41961 | 42063 |
| Operating Profit | 5631 | 6377 | 6983 | 8470 | 10258 | 11650 | 13018 | 15114 | 16501 | 17847 |
| OPM % | 21 | 22 | 21 | 25 | 27 | 27 | 27 | 29 | 28 | 30 |
| Other Income | -135 | -258 | 382 | -3449 | -3505 | 459 | 865 | 1444 | 1895 | 1537 |
| Interest | 518 | 555 | 303 | 141 | 127 | 172 | 238 | 231 | 339 | 364 |
| Depreciation | 1500 | 1753 | 2053 | 2080 | 2144 | 2529 | 2557 | 2575 | 2938 | 2976 |
| Profit before tax | 3479 | 3810 | 5010 | 2799 | 4481 | 9408 | 11088 | 13752 | 15119 | 16045 |
| Tax % | 26 | 16 | 16 | 18 | 24 | 9 | 13 | 20 | 24 | — |
| Net Profit | 2542 | 3208 | 4172 | 2272 | 3389 | 8513 | 9610 | 10965 | 11509 | 12117 |
| EPS in Rs | 8.73 | 11.11 | 15.69 | 12.1 | 13.64 | 35.32 | 39.91 | 45.55 | 47.84 | 50.41 |
| Dividend Payout % | 23 | 25 | 25 | 62 | 73 | 33 | 34 | 35 | 33 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 |
| Reserves | 36400 | 38074 | 41169 | 45025 | 46223 | 47771 | 55755 | 63427 | 71978 | 83330 |
| Borrowings | 9832 | 10385 | 10514 | 8315 | 3869 | 1290 | 6886 | 3274 | 2362 | 4627 |
| Other Liabilities | 14624 | 15598 | 12666 | 14615 | 17291 | 20474 | 17831 | 18387 | 17328 | 20210 |
| Total Liabilities | 61095 | 64297 | 64590 | 68194 | 67622 | 69776 | 80712 | 85328 | 91908 | 108407 |
| Fixed Assets | 17675 | 18853 | 21837 | 22847 | 21553 | 22665 | 24065 | 23248 | 22586 | 32822 |
| CWIP | 2801 | 2465 | 1411 | 1220 | 1567 | 1287 | 4973 | 5354 | 6644 | 3052 |
| Investments | 1192 | 7143 | 7903 | 10143 | 9612 | 12849 | 14824 | 15026 | 18354 | 24723 |
| Other Assets | 39427 | 35837 | 33439 | 33984 | 34890 | 32975 | 36849 | 41700 | 44324 | 47811 |
| Total Assets | 61095 | 64297 | 64590 | 68194 | 67622 | 69776 | 80712 | 85328 | 91908 | 108407 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 7082 | 3907 | 2196 | 6555 | 6170 | 8985 | 4959 | 12135 | 14072 | 12419 |
| Cash from Investing Activity | -4186 | -3104 | -310 | -2225 | 407 | -5556 | -7220 | -763 | -5183 | -10405 |
| Cash from Financing Activity | -2285 | -1539 | -2731 | -5715 | -5980 | -5193 | 2376 | -6710 | -7906 | -2513 |
| Net Cash Flow | 611 | -736 | -844 | -1386 | 596 | -1765 | 115 | 4662 | 983 | -498 |
| Free Cash Flow | 3492 | 2013 | -966 | 5105 | 5097 | 7550 | 2895 | 9964 | 12005 | 8906 |
| CFO/OP | 90 | 83 | 48 | 113 | 85 | 78 | 56 | 105 | 96 | 89 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 83 | 108 | 112 | 105 | 99 | 99 | 95 | 85 | 91 | 97 |
| Inventory Days | 307 | 338 | 366 | 311 | 378 | 315 | 360 | 338 | 348 | 363 |
| Days Payable | 197 | 234 | 192 | 142 | 167 | 158 | 194 | 194 | 210 | 232 |
| Cash Conversion Cycle | 193 | 212 | 285 | 274 | 310 | 255 | 261 | 229 | 228 | 228 |
| Working Capital Days | -4 | -31 | 31 | 51 | 51 | 47 | 40 | 55 | 65 | 54 |
| ROCE % | 20 | 10 | 10 | 10 | 13 | 17 | 16 | 17 | 20 | 21 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% |
| FIIs | 16.79% | 17.08% | 17.72% | 17.23% | 18.02% | 18.05% | 17.96% | 17.26% | 16.55% | 16.12% | 15.93% | 14.53% |
| DIIs | 19.57% | 17.97% | 18.72% | 19.17% | 18.5% | 18.44% | 18.59% | 19.39% | 20.13% | 20.71% | 21% | 22.07% |
| Government | 0.1% | 0% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% |
| Public | 5.56% | 5.41% | 5.44% | 5.57% | 5.43% | 5.47% | 5.42% | 5.35% | 5.53% | 5.4% | 5.3% | 5.48% |
| Others | 3.51% | 5.05% | 3.53% | 3.44% | 3.46% | 3.46% | 3.45% | 3.42% | 3.2% | 3.18% | 3.18% | 3.33% |
| No. of Shareholders | 616588 | 612626 | 631392 | 673217 | 657317 | 689623 | 704983 | 723770 | 743877 | 710900 | 690957 | 710246 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 5 / 4 / 10

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 1900.73 | Sell |
| EMA (10) | 1884.83 | Sell |
| SMA (20) | 1901.78 | Sell |
| EMA (20) | 1901.07 | Sell |
| SMA (50) | 1929.13 | Sell |
| EMA (50) | 1904.38 | Sell |
| SMA (100) | 1875.16 | Sell |
| EMA (100) | 1874.17 | Sell |
| SMA (200) | 1804.71 | Buy |
| EMA (200) | 1823.89 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 34 | Neutral |
| MACD (12,26,9) | -16.26 | Sell |
| Stochastic (14,3,3) | 6.06 | Buy |
| ADX (14) | 18.96 | Neutral |
| Williams %R (14) | -96.02 | Buy |
| ATR (14) | 32.56 | Neutral |
| ROC (12) | -3.13 | Sell |
| Stoch RSI (14) | 0 | Buy |
| UO (7,14,28) | 36.64 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 29 | 87.88% |
| Hold | 1 | 3.03% |
| Sell | 3 | 9.09% |

Based on 33 analyst ratings, observed at 2026-09-11T04:43:51.642754+00:00.

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 8h - Board meets 22 May 2026 to approve FY26 audited results and consider final dividend; trading window closed until 24 May. | [Board Meeting Intimation for Audited Standalone And Consolidated Financial Results For The Quarter And Year Ended 31 March 2026 And Recommendation Of Final Dividend For FY 2025-26 8h - Board meets 22 May 2026 to approve FY26 audited results and consider final dividend; trading window closed until 24 May.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/6a59c792-3d7c-492e-9837-128a601a08cb.pdf) |
| 8h - Audio recording of investor call on Organon & Co. acquisition available on Sun Pharma website. | [Investor Call Audio Recording 8h - Audio recording of investor call on Organon & Co. acquisition available on Sun Pharma website.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/12a7ab7c-498b-486a-b3ff-82c97780f0b1.pdf) |
| 8 May - Postal ballot approved appointing Ms. Satyavati Berera as Independent Director for five years from 08 May 2026. | [Completion And Result Of Postal Ballot Dated 07 April 2026 8 May - Postal ballot approved appointing Ms. Satyavati Berera as Independent Director for five years from 08 May 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/43699651-e7c3-443a-a3c5-f957f48dce9f.pdf) |
| 8 Apr - Of newspaper advertisements about Postal Ballot/ E-Voting | [Announcement under Regulation 30 (LODR)-Newspaper Publication 8 Apr - Of newspaper advertisements about Postal Ballot/ E-Voting](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3012791d-1902-41c5-93de-807cdb90c722.pdf) |
| 7 May - CRISIL reaffirmed AAA/A1+ ratings with watch; ICRA reaffirmed AAA Stable/A1+ after Organon acquisition announcement. | [Announcement under Regulation 30 (LODR)-Credit Rating 7 May - CRISIL reaffirmed AAA/A1+ ratings with watch; ICRA reaffirmed AAA Stable/A1+ after Organon acquisition announcement.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/ad347042-d0b6-40fc-8937-deab3bfb2b02.pdf) |
| 7 Apr - Postal ballot seeks approval to appoint Satyavati Berera as independent director; voting 9 Apr-8 May 2026. | [Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 7 Apr - Postal ballot seeks approval to appoint Satyavati Berera as independent director; voting 9 Apr-8 May 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/83e803d9-985b-4bb5-b0b3-ae9abf51e844.pdf) |
| 6 Feb - Newspaper Advertisement for special window for transfer of Physical Shares | [Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Feb - Newspaper Advertisement for special window for transfer of Physical Shares](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e1283f4f-f9dc-42a5-b24b-a986da9222c9.pdf) |
| 6 Apr - Submission of Confirmation Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31 March 2026 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Apr - Submission of Confirmation Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31 March 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9a1d4988-1cce-4102-ae89-0f3b570f7c37.pdf) |
| 5 May - Transcript: Sun Pharma - Organon Acquisition Investor Call | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript 5 May - Transcript: Sun Pharma - Organon Acquisition Investor Call](https://www.bseindia.com/xml-data/corpfiling/AttachLive/293c1789-7308-4864-982a-192b016de087.pdf) |
| 4 Feb - Q3 sales Rs154,691m, adjusted PAT Rs35,367m; interim dividend Rs11; net cash $3.2bn; Unloxcyt and SEMA launches. | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript 4 Feb - Q3 sales Rs154,691m, adjusted PAT Rs35,367m; interim dividend Rs11; net cash $3.2bn; Unloxcyt and SEMA launches.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1082d0ab-d6fb-40f5-873e-d7301397cd05.pdf) |

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-09 | [Incorporation Of A Subsidiary Company](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cec4dec1-6fc4-46d0-b791-a3c0bc226b4e.pdf) |
| 2026-09-08 | [Announcement under Regulation 30 (LODR)-Credit Rating](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5997cf9f-4814-4cf3-bc4a-ddbea79982c3.pdf) |
| 2026-09-03 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f8e31f56-d8e1-48fd-af7a-9ffa10a5ab26.pdf) |
| 2026-09-01 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4fb071ee-557f-42f8-8884-0a3cb6e8df7d.pdf) |
| 2026-08-26 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6d7426a8-ca3c-4518-ad8d-15c232579f46.pdf) |
| 2026-08-25 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=441095c7-239c-40d4-9b5a-c05243c735dc.pdf) |
| 2026-08-25 | [Shareholder Meeting / Postal Ballot-Notice of Postal Ballot](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f03c2861-5e74-40d4-b3d9-58d7c48e94ac.pdf) |
| 2026-08-17 | [Update On Lipitor Antitrust Litigation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=704b758b-75a4-4583-bf8b-7c61ffde1741.pdf) |
| 2026-08-06 | [Receipt Of No-Objection Letters From The Stock Exchanges For Reclassification Of Promoter Group](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e5b97c69-655c-44fa-b4e3-ac97837c26bb.pdf) |
| 2026-08-05 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=421d4cff-2e21-4b20-812e-023c23a4f1da.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-06 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=34be7c92-1d9f-4010-ba30-2344c959bc5e.pdf) |
| 2026-05-29 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=287022b2-8de5-487d-8d0d-77b819ee3eb4.pdf) |
| 2026-05-05 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=293c1789-7308-4864-982a-192b016de087.pdf) |
| 2026-02-04 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1082d0ab-d6fb-40f5-873e-d7301397cd05.pdf) |
| 2025-11-11 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=97dcb020-6882-4de1-8e04-97d06256d293.pdf) |
| 2025-08-06 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e9f2ef68-3852-4c76-b699-37803a05f264.pdf) |
| 2025-05-29 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3466942d-443e-4c97-8148-54b3f242e619.pdf) |
| 2025-02-06 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c64727af-4734-40b3-9dd8-dab45dd96e83.pdf) |
| 2024-11-04 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3bef8197-b43b-4a13-8773-13ec2f811511.pdf) |
| 2024-08-07 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9bca3c3b-b79b-4111-af68-679a2038beae.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-07-31 | [Unaudited Standalone And Consolidated Financial Results For Q1 Of FY 2026-27](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cc8f321b-b5b9-4f47-883d-28790c0650e3.pdf) |
| 2026-05-22 | [Financial Results For The Quarter And Year Ended 31 March 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=71784525-33ff-4631-8d3c-2bc7e9798bbd.pdf) |
| 2026-01-31 | [Unaudited Financial Results For The Quarter And Nine Months Ended 31 December 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f98cd836-0498-41d3-835b-bd611455ba9d.pdf) |
| 2025-11-05 | [Financial Results For The Quarter And Half-Year Ended 30 September 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=962c537c-a0c8-4613-98b2-cbcdcac6ce9e.pdf) |
| 2025-07-31 | [Financial Results For The Quarter Ended 30 June 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e83bf6df-02b2-4f7a-b8a7-5beb96ab4ab6.pdf) |
| 2025-05-22 | [Audited Financial Results For The Quarter And Year Ended 31 March 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=74b39d7e-b0fa-481a-b99a-827ad86869a7.pdf) |
| 2025-01-31 | [Outcome Of The Board Meeting Held Today I.E. January 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cf1218a0-7999-4c14-9df5-b8ff85b5bd34.pdf) |
| 2024-10-28 | [Financial Results For The Quarter And Half Year Ended September 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=89bd56cb-e924-44cb-8e38-401eb373d3ca.pdf) |
| 2024-08-01 | [Unaudited Financial Results For Q1 Of FY 2024-25](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2f4547b3-faf6-41d9-8f4d-91c71d429b4f.pdf) |
| 2024-01-31 | [Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=27fe62a4-23fb-429a-b5b6-9fe74421f880.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-07-31 | [Q1FY27-Investor Call Audio Recording](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b1d9ce9a-9e87-498c-88cb-f992e6c94780.pdf) |
| 2026-05-22 | [Investor Call Audio Recording](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ce101cc3-daac-4da5-9624-51a9bdaba5a8.pdf) |
| 2026-04-27 | [Investor Call Audio Recording](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=12a7ab7c-498b-486a-b3ff-82c97780f0b1.pdf) |
| 2026-01-31 | [Q3FY26 Earnings Call Audio Recording](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fe19d494-870f-4508-af81-37b62c0dc0b8.pdf) |
| 2025-11-05 | [Investor Call Audio Recording](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=12a54720-8836-40fc-840f-875a4672d699.pdf) |
| 2025-07-31 | [Sun Pharmas Q1FY26 Investor Call Audio Recording](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e66f48fa-6352-44dd-9294-df434c2faa89.pdf) |
| 2025-05-22 | [Investor Audio Call Recording](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9b296a88-054e-4726-bc5e-c9f69697814f.pdf) |
| 2025-01-31 | [Q3FY25 Investor Call Audio Recording](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3d9f19cb-9059-4a8e-9733-e086fb69605c.pdf) |
| 2024-10-28 | [Q2FY25 Investor Call Audio Recording](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f9df09b3-0c74-4ab7-b612-9a338c2f6368.pdf) |
| 2024-08-01 | [Investor Call Audio Recording](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ef09dd3f-f956-4b5e-8670-7b9a5f9b82f8.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-07-07 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e6f00b4f-5f46-44d8-a2d2-db50b7cc28ff.pdf) |
| 2026-04-27 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6fb0611b-17c4-4e4b-8730-63f76028c1a1.pdf) |
| 2026-02-24 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8ef19f3e-b9ef-4842-9ad9-d0b0120afe72.pdf) |
| 2025-12-26 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e01bfcbf-aaae-4101-a746-c13ec04f062e.pdf) |
| 2025-09-01 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=53bd47d5-f08c-4abf-89dc-c111d452ca8e.pdf) |
| 2025-07-14 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=811dac05-9dcf-4c75-8db4-54806ab875d4.pdf) |
| 2025-03-04 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=34807459-abf9-47bd-ae8e-0c309ade4bfc.pdf) |
| 2024-11-28 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=589346d5-d3f2-4e8b-b7fc-6eb84985195c.pdf) |
| 2024-09-30 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d1a69652-c883-440b-9e3f-81881aaf438e.pdf) |
| 2024-07-10 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c61aaa1c-2fbc-4700-a3aa-ae2a122aca3d.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Sep 2025 | [Concall - Sep 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e9f2ef68-3852-4c76-b699-37803a05f264.pdf) |
| Sep 2024 | [Concall - Sep 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d1a69652-c883-440b-9e3f-81881aaf438e.pdf) |
| Sep 2023 | [Concall - Sep 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f5893923-3593-415f-a2b6-0e52610a6264.pdf) |
| Oct 2024 | [Concall - Oct 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0605915b-66be-46c5-b33f-ee6c256091a8.pdf) |
| Oct 2024 | [Concall - Oct 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0605915b-66be-46c5-b33f-ee6c256091a8.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/97dcb020-6882-4de1-8e04-97d06256d293.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3bef8197-b43b-4a13-8773-13ec2f811511.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/788eb9c4-2be4-4e46-a1bc-045cc355fed6.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/287022b2-8de5-487d-8d0d-77b819ee3eb4.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/287022b2-8de5-487d-8d0d-77b819ee3eb4.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cb65dea5-416a-4f98-95e2-0b58761b7442.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/511405ab-48e8-4d89-84af-aaa2e083e816.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a1e3c7fc-c47e-4ce8-ad92-b4affd2a9cf8.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T20:00:00.796Z.